LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discovery? version 1.5 (discovery.lifemapsc.com). LifeMap Discovery? is a state-of-the-art roadmap of embryonic development and ...
US-based biotechnology firm BioTime has entered into a sublicense agreement with Jade Therapeutics, a developer of ophthalmic sustained-release drug delivery platforms, for ophthalmic drug delivery applications of BioTime's HyStem ...
Tags: Health, Medicine, biotechnology
BioTime has signed an exclusive licensing deal for stroke treatment technology with the University of California, Los Angeles (UCLA). The licensed technology leverages one of BioTime's HyStem hydrogels for localized delivery of growth ...
US-based biotechnology company BioTime and its subsidiary LifeMap Sciences have entered into a definitive data mining collaboration agreement. Under the agreement, BioTime will use LifeMap's computer-based tools to extract information ...
Tags: biotechnology company, PureStem progenitor cell, biotechnology
BioTime and its wholly owned subsidiary, LifeMap Sciences, have announced an agreement to purchase XenneX. The acquisition, which is expected to close within 30 days, will merge XenneX into LifeMap Sciences. The deal is expected to ...
Tags: BioTime, XenneX, LifeMap Sciences
LifeMap Sciences, a subsidiary of BioTime, has introduced a database platform of human cellular life to advance research in the stem cell and other biomedical fields, and develop new diagnostic technologies and therapeutic products. The ...
XenneX, a division of LifeMap Sciences, and BioTime have announced the availability of GeneCards Version 3.08. The new release includes more than 94,500 gene entries, displays about 52,000 non-protein-coding RNA genes and also shows ...
Tags: new version of clinical database, clinical industry, new product
BioTime has signed an exclusive sublicense agreement and a supply agreement with Jade Therapeutics for ophthalmological drug delivery applications of HyStem technology. According to the agreement, BioTime will provide Jade with ...
Tags: HyStem technology, Biotime, Jade Therapeutics, ophthalmological drug